Sustained-Release Technology for Prevention of Complications of Cataract Surgery in Diabetic Patients
Abstract
The proposed project addresses the Fiscal Year 2019 Peer Reviewed Medical Research Program Area of Encouragement: Diabetes: Research on interventions to prevent or treat diabetes complications. Cataracts are a common, sight-threatening complication of diabetes. Patients with diabetes have a greater overall risk of developing cataracts than non-diabetics, and they develop cataracts at a younger age than non-diabetics. The standard treatment for cataracts is cataract surgery. Studies have shown that patients with diabetes are at greater risk of complications from cataract surgery than non-diabetics. One such complication involves injury to the corneal endothelium – the inside surface of the cornea. There are currently no approved treatments or preventions for corneal injury from cataract surgery. LayerBio is developing a novel therapy based on its proprietary OcuRing™ drug delivery platform that provides continuous release of medications to prevent such complications in diabetic patients undergoing cataract surgery. The aims of this project include nonclinical safety studies and manufacturing process development necessary to file an Investigational New Drug (IND) application with the Food and Drug Administration (FDA). Successful completion of these aims will enable initiation of clinical trials to demonstrate safety and efficacy of our technology in diabetic patients undergoing cataract surgery. It will also further validate the OcuRing™ platform as a method of drug delivery for related eye diseases.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Jun 29, 2021
- Source ID
- W81XWH2010489
Entities
People
- Kenneth Mandell
Organizations
- United States Army